Precision Medicine in Oncology
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
Giants of Cancer Care
Precision Medicine in Oncology
<< View More Conferences
2018 ESMO Congress
Oncology Conference Multimedia
View more videos >>
ESMO 2018: Dr. Ramalingam Shares Insight on Lung Cancer Studies
ESMO 2018: Dr. Verma Sheds Light on Breast Cancer Data
ESMO 2018: Dr. Abou-Alfa Discusses Updates in GI Cancer
Oncology Conference Articles
Frontline Alectinib Outperforms Crizotinib in Asian Patients With ALK+ NSCLC
Asian patients with untreated
-positive advanced NSCLC lived significantly longer without disease progression if they received the next-generation tyrosine kinase inhibitor alectinib instead of crizotinib as initial therapy.
Neoadjuvant Nivolumab Plus Ipilimumab Active in dMMR Early-Stage Colon Cancer
First results from a study of neoadjuvant ipilimumab plus nivolumab in patients with early-stage colon cancer found a major pathologic response achieved in all 7 patients with mismatch repair deficient tumors.
Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel Improves OS in Nonsquamous NSCLC
The first-line triplet of atezolizumab, carboplatin, and nab-paclitaxel was associated with a statistically significant improvement in both progression-free and overall survival compared with chemotherapy alone in patients with stage IV nonsquamous NSCLC, according to results from the phase III IMpower130 trial.
Cisplatin Remains Standard for Low-Risk HPV+ Oropharyngeal Cancer
Cisplatin plus radiotherapy results in better overall survival and the same rate of all-grade toxicity compared with cetuximab plus radiotherapy in patients with HPV-positive oropharyngeal cancer.
Long-Term Data Sustain Dabrafenib/Trametinib RFS Benefit in BRAF+ Melanoma
Long-term follow-up from the COMBI-AD trial continued to show a significant relapse-free survival advantage for patients with resected stage III
-mutant melanoma treated with adjuvant dabrafenib plus trametinib.
Trifluridine/Tipiracil Extends Survival in Heavily Pretreated Gastric/GEJ Cancer
Trifluridine/tipiracil reduces the risk of death by about one-third compared with placebo in patients with heavily pretreated gastric or gastroesophageal junction cancer.
Pembrolizumab Improves OS, but Not PFS and ORR in Frontline HNSCC
Frontline pembrolizumab monotherapy showed an improvement in overall survival and duration of response versus standard therapy in patients with PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma; however, there was not a similar improvement in progression-free survival or overall response rate with the PD-1 inhibitor.
Atezolizumab Plus Bevacizumab Shows Durable Activity in Advanced HCC
The combination of the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab showed promising and durable antitumor activity in a phase Ib study of patients with advanced hepatocellular carcinoma.
Rucaparib Responses Reached in Nearly Half of Men With BRCA+ mCRPC
Preliminary data from the ongoing phase II TRITON2 trial demonstrated a 44% confirmed objective response rate by investigator assessment among evaluable men with
-mutated metastatic castration-resistant prostate cancer who were treated with the PARP inhibitor rucaparib.
Higher Dose of Ipilimumab Added to Nivolumab Effective in Bladder Cancer
Extended follow-up data from the CheckMate-032 study shows a trend toward higher overall response and longer progression-free survival with the regimen of nivolumab at 1 mg/kg plus ipilimumab at 3 mg/kg in patients with platinum-pretreated metastatic urothelial carcinoma.
Entrectinib Active Across Multiple Tumor Types
More than half of patients with advanced solid tumors associated with
gene fusions responded to treatment with the small-molecule inhibitor entrectinib, an integrated analysis of 3 clinical trials showed.
Olaparib Substantially Improves PFS as Frontline Maintenance in Ovarian Cancer
The PARP inhibitor olaparib significantly improved progression-free survival as frontline maintenance therapy for women with
-positive advanced ovarian cancer, according to findings from the randomized phase III SOLO-1 trial.
Larotrectinib Demonstrates High Response Rate, Durability in NTRK+ Cancers
Patients with advanced cancers associated with NTRK gene fusions had an 80% objective response rate with the TRK inhibitor larotrectinib, pooled results from three small trials showed.
Tepotinib Plus Gefitinib Improves PFS in MET+ EGFR-Mutant NSCLC
The combination of tepotinib plus gefitinib improved progression-free survival and overall response versus chemotherapy in patients with
-positive non–small cell lung cancer resistant to prior EGFR TKI therapy.
Engineered Anti-MAGE-A T-Cells Show Early Promise
Genetically engineered T-cells targeting a common tumor antigen appeared safe and demonstrated some evidence of antitumor activity in a first-in-human clinical evaluation.
Radiotherapy Raised to New Standard in Newly Diagnosed Prostate Cancer With Low Metastatic Burden
When added to standard of care therapy, radiotherapy to the prostate improves overall survival in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden.
Avelumab/Axitinib Nearly Doubles PFS, ORR in Frontline RCC
The combination of avelumab and axitinib doubled objective response rates and significantly improved progression-free survival compared with sunitinib in patients with treatment-naïve advanced renal cell carcinoma regardless of PD-L1 expression.
Niraparib Effective in Later Lines of Therapy for Relapsed Ovarian Cancer
The PARP inhibitor niraparib has shown durable clinical activity in later lines of therapy in patients with relapsed ovarian cancer who have
mutations, according to a posthoc analysis of the phase II QUADRA study.
Alpelisib Combo Nearly Doubles PFS in PIK3CA-Mutant Breast Cancer
The addition of the PI3K inhibitor alpelisib to fulvestrant nearly doubled median progression-free survival compared with the endocrine therapy alone in patients with HR-positive/HER2-negative advanced breast cancer who have a
OS Benefit Confirmed With Palbociclib Combo in Pretreated HR+/HER2- Breast Cancer
The combination of palbociclib plus fulvestrant led to a clinically meaningful benefit in overall survival in patients with hormone receptor–positive, HER2-negative advanced breast cancer who had progressed or relapsed on prior endocrine therapy.
RCC Gene Signatures Validated for Treatment Benefit
Distinct gene signatures in renal cell carcinoma correlated with improved progression-free survival with immunotherapy or a targeted agent, according to a new analysis of the phase III IMmotion151 trial.
Atezolizumab Combo Improves PFS in Frontline Metastatic TNBC
The addition of atezolizumab to nab-paclitaxel reduced the risk of progression or death by 38% compared with nab-paclitaxel alone in patients with PD-L1–positive metastatic triple-negative breast cancer.
Adding Radium-223 to Abiraterone Shows No Survival Advantage in mCRPC
Adding radium-223 dichloride to abiraterone acetate and prednisone did not improve survival in patients with metastatic castration-resistant prostate cancer.
MET, EGFR C797S Linked With Acquired Resistance to Frontline Osimertinib in NSCLC
C797S mutations are the most commonly observed alterations associated with resistance to first-line osimertinib in patients with
-mutant non–small cell lung cancer.
FDA Approval of a Biosimilar, Promising Data in Myeloma and GBM, and More
CDK4/6 Inhibitors Show Unmatched OS Benefit in Metastatic HR+ Breast Cancer
Dr. Giralt on Evaluating MRD in Multiple Myeloma
Molecular Testing for CCA
Secondary Cytoreduction Does Not Improve Survival in Recurrent Ovarian Cancer
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2019
Intellisphere, LLC. All Rights Reserved.